27. Grenga, I., et al., Anti -PD-L1/TGFbetaR2 (M7824) fusion prot ein induces immuno genic modulation of human urothelial carcinoma c ell lines, rendering them more susceptible to immune -mediated rec ognition and lysis. Ur ol Oncol, 2018. 36 (3): p . 93 e1 -93 e11. 28. Jochems, C., et al., Analyses of functions of an anti- PD-L1/TGFbetaR2 bispeci fic fusion protein (M7824) . Oncotarget, 2017. 8(43): p. 75217-75231. Abbreviated T itle: STAT Trial Version Date : 08/17/2022 119 29. Knudson, K.M., et al., M7824, a novel bifunctional anti- PD-L1/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology, 2018. 7(5): p. e1426519. 30. Lan, Y., et al., E nhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD- L1 and TGF-beta. Sci Transl Med, 2018. 10(424). 31. Ravi, R., et al., Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFbeta enhance the efficacy of cancer immunotherapy. Nat Commun, 2018.